Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234702 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease
A Phase 2 study of Kidney Diseases, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 10
- Study locations
NCT00234702 is a Phase 2 study of Kidney Diseases that has completed, run by Shire. The registered enrollment target is 84 participants, below the 1,783-participant average among 38 other Kidney Diseases trials with a reported enrollment target (95% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT00234702, a Phase 2 study of Kidney Diseases, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 10
- Study locations
Study Summary
Chronic kidney disease (CKD) can result in a loss of ability to filter and excrete phosphate. The body's attempt to adjust to an increased level of phosphate in the blood can result in elevated levels of hormones and minerals resulting in serious clinical consequences. This study is being conducted to evaluate the safety and efficacy of lanthanum carbonate in lowering high levels of phosphorus in the blood in subjects with CKD Stages 3 and 4 compared to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lanthanum carbonate
Study Locations (10)
California
- VA Greater Los Angeles Health Care System - Los Angeles
- Barnett Research & Communications Medical Corporation - Torrance
Colorado
- Western Nephrology & Metabolic Bone Disease, PC - Thornton
Florida
- Outcomes Research International, Inc. - Hudson
Minnesota
- Twin Cities Clinical Research - Brooklyn Center
Missouri
- St. Louis University/Nephrology - St Louis
North Carolina
- University of North Carolina - Chapel Hill
Oregon
- Northwest Renal Clinic - Portland
Tennessee
- Nephrology Associates - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2006-01-11 |
| Est. Completion | 2007-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00234702
The ClinicalTrials.gov registry entry for NCT00234702 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,783-participant average among 38 other Kidney Diseases trials with a reported enrollment target (95% lower). The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00234702 reports 10 study locations spanning 9 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT00234702 about?
NCT00234702 is a clinical study titled "Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease". Chronic kidney disease (CKD) can result in a loss of ability to filter and excrete phosphate. The body's attempt to adjust to an increased level of phosphate in the blood can result in elevated levels of hormones and minerals resulting in serious clinical consequences. This study is being conducted ...
What is the current status of trial NCT00234702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2006-01-11. Estimated completion is 2007-06-01.
What conditions does trial NCT00234702 study?
This clinical trial studies the following conditions: Kidney Diseases.
What interventions are being tested in trial NCT00234702?
The interventions under investigation include: Placebo (DRUG), Lanthanum carbonate (DRUG).
Who is sponsoring clinical trial NCT00234702?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00234702 being conducted?
This trial has 10 study locations across California, Colorado, Florida, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
COMPLETED · Phase 2
-
A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures
COMPLETED · Phase 2
-
Collaborative Learning to Achieve Refined Interventions for Emory: Kidney Disease
RECRUITING · NA
-
Rutgers University Study of the Genetics of Kidney Disease
RECRUITING
-
Supporting VETerans With Kidney Disease Through Food As Medicine
RECRUITING · NA
-
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.